The United States of America, As Represented by the Secretary, Department of Health and Human Services

Other

Wisconsin Alumni Research Foundation

Georgia Tech Research Corporation

Emory University

Perkinelmer Health Sciences, Inc.

Children's Healthcare of Atlanta, Inc.

University of Georgia Research Foundation, Inc.

Larry J Anderson

Ralph A Tripp

Thomas G Ksiazek

Anthony Sanchez

Pierre E Rollin

Cara Carthel Burns

Raymond Campagnoli

M Steven Oberste

William Allan Nix

Paul A Rota

Mark A Pallansch

James A Comer

Dean D Erdman

Suxiang Tong

Stephan S Monroe

Michael Paul Brown

Cynthia Goldsmith

William J Bellini

Sherif R Zaki

Teresa C T Peret

Joseph P Icenogle

Charles D Humphrey

Shannon L Emery

Qi Chen

Les Jones

Lia M Haynes

George Kadlicko

David N Ku

Harris L Bergman

Colin G Potter

Matthew Peter Christensen

Binh Ha

Deborah D Moore

Elizabeth R Wright

Wun-Ju Shieh

Christopher D Paddock

Richard F Meyer

Jeanette Guarner

Byron T Cook

Michael D Bowen

Tamera Scholz

Prem A Midha

The present disclosure relates to virus-like particles and vaccine compositions for inducing immunity and preventing respiratory syncytial virus (RSV) infection. Specifically, the disclosure provides virus like-particles (VLPs) for use in inducing immunity to respiratory syncytial virus (RSV) infections or symptoms thereof, wherein the VLP comprising a respiratory RSV matrix protein (M) and an RSV M2-1 protein, a glycoprotein (G), a fusion protein (F), and/or a phosphoprotein (P).

RSV virus-like particles and methods of use thereof

Immunogenic polypeptides corresponding to one or more RSV G glycoproteins, or analogues thereof, are provided as components of vaccines. The inventive compositions are useful as both a prophylactic and therapeutic for the prevention and treatment of RSV infections and associated pulmonary or other diseases. The inventive immunogens include regions of the RSV G protein, specifically, amino acid residues 164-176 of RSV G A2 protein or analogues thereof. This inventive immunogen is operable alone or in combination with other polypeptides such as the RSV G protein amino acid residues 155-206, or other vaccines such as live RSV vaccines, or inactivated RSV vaccines or immunogenic analogues thereof.

Anti-RSV immunogens and methods of immunization

A device for collecting material from lung aerosols. The device functions by collecting aerosols from the lower airway separated from material in the by collecting air from the upper airway in a chamber that when full causes the remaining exhaled aerosols from the lungs to be captured by a filter. The filter collects sample of material from the separated lung aerosols.

Lung aerosol collection device

Compositions and methods are provided for the treatment or prevention of RSV disease by modulating RSV infection and immunity. In particular, amino acid sequences in the RSV G glycoprotein, containing the chemokine motif defined as C-X-X-X-C (or CX3C), are identified that are essential in causing RSV infection and disease. The chemokine motif is biologically active and participates in virus binding to and infection of susceptible cells. The prevention or treatment of RSV infection is achieved by interfering with the motif, such as by administering a vaccine in which the motif is altered or by administration or induction of blocking molecules that inhibit the biological activity of the motif.

Compositions and methods for modulating RSV infection and immunity

Immunogenic polypeptides corresponding to one or more RSV G glycoproteins, or analogs thereof, are provided as components of vaccines. The inventive compositions are useful as both a prophylactic and therapeutic for the prevention and treatment of RSV infections and associated pulmonary or other diseases. The inventive immunogens include regions of the RSV G protein, specifically, amino acid residues 164-176 of RSV G A2 protein or analogs thereof. This inventive immunogen is operable alone or in combination with other polypeptides such as the RSV G protein amino acid residues 155-206, or other vaccines such as live RSV vaccines, or inactivated RSV vaccines or immunogenic analogs thereof.

The present invention provides methods and adjuvants for enhancing an immune response to RSV in a host, wherein the methods and adjuvants comprise a source of a CD40 binding protein. Preferably, the CD40 binding protein is CD40L and the source is a vector comprising a promoter operatively linked to a CD40L coding region. The enhanced immune response produced by the adjuvants and methods of the current invention includes both increased expression of Th1 cytokines and increased production of antibody.

CD40 ligand adjuvant for respiratory syncytial virus

Disclosed herein is a newly isolated human coronavirus (SARS-CoV), the causative agent of severe acute respiratory syndrome (SARS). Also provided are the nucleic acid sequence of the SARS-CoV genome and the amino acid sequences of the SARS-CoV open reading frames, as well as methods of using these molecules to detect a SARS-CoV and detect infections therewith. Immune stimulatory compositions are also provided, along with methods of their use.

Coronavirus isolated from humans

Cd40 ligand adjuvant for respiratory syncytial virus

The present invention provides methods for preventing or treating a disease in a subject which is caused by an inflammatory response to a disease or syndrome which is mediated by endogenous substance P. These methods comprise the administration to the subject of a pharmaceutically-effective amount of anti-substance P antibodies, or anti-substance P antibody fragments, such as F(ab)fragments, thereby inhibiting the activity of endogenous substance P in the subject. By inhibiting the activity of endogenous substance P in the subject, the levels of cytokines produced by T lymphocytes present in the subject are reduced, the signals which direct the inflammatory response to the infection become altered, and the amount of cytokine-induced inflammation becomes reduced. Respiratory syncytial virus is one example of an agent which causes an infection which often results in a disease caused by an inflammatory response to the infection mediated by endogenous substance P. Generally, from about 0.001 mg to about 10 g of anti-substance P antibodies, or anti-substance P antibody fragments, per kilogram of body weight per day are administered to a mammalian subject, with from about 1 mg to about 1000 mg of anti-substance P antibodies, or anti-substance P antibody fragments, per kilogram of body weight per day being preferred.

Method for the prevention and treatment of diseases caused by an inflammatory response mediated by endogenous substance P by using anti-substance P antibodies

A hydraulic motor comprising a housing having a fluid inlet. A fluid outlet and a cavity there between, a pair of intermeshing gear elements rotatable in the housing about mutually parallel axes. Each of the gear elements having a set of gear teeth disposed about the periphery of the element and a support shaft extending from oppositely directed end faces of the set of gear teeth. A bearing assembly located on opposite sides of the cavity in said housing to support the shafts for rotation about respective ones of the axes. Each of the bearing assemblies having a sealing face overlying the end faces and biased into engage with the end faced by a pressure compensating seal located between the bearing and the housing. The sealing face having a channel extending partially about the spindle and in fluid communication with the inlet to introduce fluid under pressure between the faces.

Gear motor start up control

Apparatus for measuring chemiluminescence of multiple samples on a

Growing community of inventors

Atlanta, GA, United States of America

Larry J Anderson